Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
641-660 of 847 trials

Aggressive Multiple Sclerosis: Stem Cell Transplant Study

We are investigating whether stem cell transplantation can prevent disease activity in people with aggressive multiple sclerosis. The study will also monitor safety and other health changes over time.

Relapsing-Remitting Multiple Sclerosis>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyNeurology

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: INBRX-106 with Pembrolizumab

We are studying whether adding INBRX-106 to pembrolizumab helps patients with recurrent or metastatic head and neck cancer. This trial focuses on effectiveness, safety, and quality of life for those with high PD-L1 expression.

Head and Neck Squamous Cell CarcinomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Kidney Transplant: Belatacept vs. Anticalcineurins

We are studying whether switching from anticalcineurins to Belatacept improves blood vessel function and reduces arterial stiffness in kidney transplant patients. This may help enhance overall cardiovascular health.

Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology

Bone Health: AGA2118 for Postmenopausal Women

We are studying whether AGA2118 can improve bone density in postmenopausal women with low bone mass. The trial compares its effects to a placebo over 12 months.

Postmenopausal OsteoporosisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyOrthopedics and TraumatologyRheumatology

Polypoidal Choroidal Vasculopathy: Faricimab Injections

We are studying the effects of faricimab injections on vision improvement in Caucasian patients with polypoidal choroidal vasculopathy. The trial will also assess the treatment's safety and durability.

Polypoidal Choroidal Vasculopathy>2 yearsMonitoring phase (IV)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOphthalmology

Chronic Lymphocytic Leukemia: APG-2575 Study

We are studying a new medication, APG-2575, for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial will evaluate its safety and effectiveness alone and with other treatments.

Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Lung Cancer Treatment: Adagrasib with Pembrolizumab

We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncology

Episodic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with episodic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Optic Pathway Glioma: CHF6467 Eye Drops

We are studying the safety and effectiveness of a new eye drop treatment for children and young adults with optic pathway gliomas. This trial aims to see if it can improve their vision.

Optic Glioma≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyOphthalmology

Functional Dyspepsia: Rikkunshito Study

We are investigating whether Rikkunshito can help relieve symptoms in patients with functional dyspepsia. The study also looks at how it may affect the digestive lining and overall gut function.

Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Non-Small Cell Lung Cancer: BNT327 with Chemotherapy

We are studying the safety and effectiveness of BNT327, an investigational therapy, combined with chemotherapy for patients with non-small cell lung cancer. This trial compares it to standard treatments to see which works better.

Non-small cell lung cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pulmonary Hypertension: Sotatercept Study

We are investigating the safety and effects of sotatercept in individuals with pulmonary hypertension due to heart failure. This study aims to understand how well the treatment works over time.

Pulmonary Hypertension>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Chronic Low Back Pain: Antibiotic Treatment Study

We are studying whether a three-month course of amoxicillin can help people with chronic low back pain and specific MRI changes. This trial compares the antibiotic treatment to a placebo to see if it offers any benefits.

Non-Specific Low Back Pain1-2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine